A significantly higher proportion of patients with moderately to severely active ulcerative colitis treated with risankizumab achieved the primary endpoint of clinical remissiona (per Adapted Mayo Score) compared to placebo at week 12 in the Phase 3 INSPIRE induction study
All secondary endpoints, including clinical, endoscopic and histologic outcomes, were met
Safety results in this study were consistent with the known safety profile of risankizumab, with no new safety risks observed1
Building on AbbVie's growing gastroenterology portfolio, risankizumab is an IL-23 inhibitor being evaluated as a treatment for adults with moderate to severe ulcerative colitis and approved for Crohn's disease, psoriatic arthritis, and psoriasis1
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.